Posts

Showing posts with the label APOE4 homozygous Alzheimer’s disease (AD)

APOE4 Homozygous Alzheimer’s Disease (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Alzheimer's disease (AD) is a progressive neurodegenerative disease associated with cognitive decline and is the most common form of dementia in the elderly. Approximately 13% of people over the age of 65 and 45% over the age of 85 are estimated to have AD. The imbalance between the production and clearance of amyloid-β (Aβ) peptides in the brain results in the accumulation and aggregation of Aβ. The toxic Aβ aggregates in the form of soluble Aβ oligomers, intraneuronal Aβ, and amyloid plaques injure synapses and ultimately cause neurodegeneration and dementia. The toxicity of Aβ seems to depend on the presence of microtubule-associated protein tau, the hyperphosphorylated forms of which aggregate and deposit in AD brains as neurofibrillary tangles. Aβ is composed of 40 or 42 amino acids and is generated through proteolytic cleavage of the amyloid precursor protein. Early-onset familial AD, which typically develops before the age of 65 years and accounts for only a small portion (...

APOE4 homozygous Alzheimer’s disease (AD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
  Alzheimer's disease (AD) is a progressive neurodegenerative disease associated with cognitive decline and is the most common form of dementia in the elderly. Approximately 13% of people over the age of 65 and 45% over the age of 85 are estimated to have AD. The imbalance between the production and clearance of amyloid-β (Aβ) peptides in the brain results in the accumulation and aggregation of Aβ. The toxic Aβ aggregates in the form of soluble Aβ oligomers, intraneuronal Aβ, and amyloid plaques injure synapses and ultimately cause neurodegeneration and dementia. The toxicity of Aβ seems to depend on the presence of microtubule-associated protein tau, the hyperphosphorylated forms of which aggregate and deposit in AD brains as neurofibrillary tangles. Aβ is composed of 40 or 42 amino acids and is generated through proteolytic cleavage of the amyloid precursor protein. Early-onset familial AD, which typically develops before the age of 65 years and accounts for only a small portion ...

APOE4 homozygous Alzheimer’s disease (AD) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Image
  Alzheimer's disease (AD) is a progressive neurodegenerative disease associated with cognitive decline and is the most common form of dementia in the elderly. Approximately 13% of people over the age of 65 and 45% over the age of 85 are estimated to have AD. The imbalance between the production and clearance of amyloid-β (Aβ) peptides in the brain results in the accumulation and aggregation of Aβ. The toxic Aβ aggregates in the form of soluble Aβ oligomers, intraneuronal Aβ, and amyloid plaques injure synapses and ultimately cause neurodegeneration and dementia. The toxicity of Aβ seems to depend on the presence of microtubule-associated protein tau, the hyperphosphorylated forms of which aggregate and deposit in AD brains as neurofibrillary tangles. Aβ is composed of 40 or 42 amino acids and is generated through proteolytic cleavage of the amyloid precursor protein. Early-onset familial AD, which typically develops before the age of 65 years and accounts for only a tiny portion (...